Drugs Made In America Acquisition announced a financing arrangement with BV Advisory Partners that includes a $500,000 commitment under a Definitive Interim Investment and Sponsor Transition Agreement and the issuance of a $100,000 Interim Convertible Note as the first tranche. The interim note matures in six months, bears no interest, and may convert at a 35% discount to market upon completion of an initial business combination. A second tranche of $200,000 is expected within 21 days, with the balance available as needed, and the investor may provide additional funds. The company will use proceeds for accounting, audit, and other business combination-related expenses, and will seek to provide the investor with not less than 40% sponsor-level economics.
Agreement 1: Drugs Made In America Acquisition Issues $100,000 Interim Convertible Note at 35% Discount
- Agreement type: Interim convertible note financing
- Counterparty: BV Advisory Partners
- Signed / Effective: Mar 23 2026 / Mar 23 2026
- Duration / Termination: 6 months
- Reason: Bridge funding for SPAC transaction costs and deal pursuit
Agreement 2: Drugs Made In America Acquisition Secures $500,000 Financing Commitment From BV Advisory Partners
- Agreement type: Definitive interim investment and sponsor transition agreement for convertible note financing
- Counterparty: BV Advisory Partners
- Signed / Effective: Mar 23 2026 / Mar 23 2026
- Duration / Termination: At will
- Reason: Secure bridge financing to pursue a business combination
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.